ReviewImmunoTargets and therapy2016
Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies.
Review in ImmunoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 70 citations in OpenAlex.
- Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.Blood advances · 2026Article
- A case of diagnosis and treatment of mediastinal Langerhans cytosis.Journal of cardiothoracic surgery · 2025Article
- Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.Cancer reports (Hoboken, N.J.) · 2024Review
- Langerhans cell histiocytosis of the skull in 23 children.European journal of medical research · 2024Article
- Langerhans cell histiocytosis oral lesions in pediatric patients.Acta odontologica latinoamericana : AOL · 2023Article
- BRAF-V600E utilizes posttranscriptional mechanisms to amplify LPS-induced TNFα production in dendritic cells in a mouse model of Langerhans cell histiocytosis.Journal of leukocyte biology · 2022Article
- Langerhans cell histiocytosis: Presentation in a preterm neonate.Cancer reports (Hoboken, N.J.) · 2022Article
- Multifocal Langerhans cell histiocytosis in a child.Radiology case reports · 2021Article
- Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis.Frontiers in oncology · 2021Article
- Case Report: Early Association of Vemurafenib to Standard Chemotherapy in Multisystem Langerhans Cell Histiocytosis in a Newborn: Taking a Chance for a Better Outcome?Frontiers in oncology · 2021Article
- Secondary pulmonary hypertension due to pulmonary Langerhans cell histiocytosis accompanied with panhypopituitarism.Respirology case reports · 2021Article
- Adult pulmonary Langerhans cell histiocytosis revealed by central diabetes insipidus: A case report and literature review.Molecular and clinical oncology · 2020Article
- Article
- Congenital Langerhans cell histiocytosisBiomedica : revista del Instituto Nacional de Salud · 2020Review
- Primary Oro-Facial Manifestations of Langerhans Cell Histiocytosis in Pediatric Age: A Bi-Institutional Retrospective Study on 45 Cases.Children (Basel, Switzerland) · 2020Article
- Langerhans Cell Histiocytosis with Isolated Cutaneous Involvement Refractory to Polychemotherapy: A Case Report.The Journal of clinical and aesthetic dermatology · 2020Article
- Langerhans cell histiocytosis of a metatarsal bone in an adult female.BMJ case reports · 2019Article
- Diffuse, fracturing systemic skeletal histiocytosis of unknown type: a novel metabolic bone disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Article
- Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment.Postepy dermatologii i alergologii · 2018Review
- [Vemurafenib in refractory langerhans histiocytosis].Developmental period medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than a century after its first description, Langerhans cell histiocytosis (LCH) still remains an intriguing disease. Considerable progress in understanding its biology has been achieved recently. Description of the V600E BRAF mutation in samples of LCH tissue in 2010 was followed by description of additional mutations, all leading to constitutive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.